Advertisement
Advertisement
Rallybio Corporation Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsRallybio Corporation Reports Q2 2025 Financial Results
3M ago
Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition
Premium
Company Announcements
Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition
4M ago
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
Premium
Market News
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement
4M ago
Rallybio Finalizes Employment Agreement with CMO
PremiumCompany AnnouncementsRallybio Finalizes Employment Agreement with CMO
5M ago
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization
Premium
Company Announcements
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization
5M ago
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk
Premium
Company Announcements
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk
5M ago
Rallybio downgraded to Hold from Buy at JonesResearch
PremiumThe FlyRallybio downgraded to Hold from Buy at JonesResearch
7M ago
Rallybio downgraded to In Line from Outperform at Evercore ISI
Premium
The Fly
Rallybio downgraded to In Line from Outperform at Evercore ISI
7M ago
Rallybio downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Rallybio downgraded to Neutral from Buy at H.C. Wainwright
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100